Study of CM310 in Subjects With Seasonal Allergic Rhinitis

Launched by KEYMED BIOSCIENCES CO.LTD · Dec 6, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called CM310 for people who suffer from seasonal allergic rhinitis, which is a type of allergy that happens at certain times of the year due to pollen and other allergens. The trial aims to see how well CM310 works in reducing allergy symptoms. It is still in the planning stages and has not started recruiting participants yet.

To be eligible for this study, participants need to be between 18 and 65 years old and should be able to understand the study details and agree to participate by signing a consent form. They must also take precautions to prevent pregnancy during the study. However, people who have certain allergies, are taking other investigational drugs, or have specific medical conditions, like tumors in the nasal area, will not be able to participate. If you join the study, you will be monitored by doctors and other researchers to assess the effectiveness of the treatment and ensure your safety throughout the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female aged 18-65.
• • Understand the study and sign the Informed Consent Form voluntarily.
• • Take effective contraception measures throughout the study period.
• Exclusion Criteria:
• • Used other investigational drugs.
• • Allergies to drugs with IL-4Rα monoclonal antibody or drug components of CM310.
• • Plan to participate in other studies during this clinical trial.
• • With malignant or benign tumors of the nasal cavity.
• • Other reasons the researcher believes that the subject is not suitable to participate in this study.